Delay in Submission of Financial Results for the period ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vanta Bioscience has postponed its board meeting originally scheduled for May 30, 2025, which was meant to consider and approve the audited standalone and consolidated financial results for the half year and year ended March 31, 2025. The reason given is a delay in receiving accounts from the company's Associate Company, which prevents preparation of consolidated results within the SEBI-mandated deadline of May 30, 2025 under Regulation 33 of the Listing Regulations. The company has stated that a revised date for the board meeting will be communicated in due course. The trading window for designated persons remains closed until 48 hours after the conclusion of the postponed board meeting.
This is a regulatory compliance delay rather than a signal of financial distress, but investors should note that audited results are overdue and a new timeline has not been provided. The stock may face short-term uncertainty, and the company could attract BSE/SEBI scrutiny for late submission of results.